Search company, investor...

Founded Year



Series C | Alive

Total Raised


Last Raised

$14.94M | 23 days ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+130 points in the past 30 days

About Arzeda

Arzeda is a synthetic biology company that creates proteins, enzymes, and specialty chemicals for polymers, pharmaceuticals, industrial chemicals, and other advanced applications. The company was founded in 2007 and is based in Seattle, Washington.

Headquarters Location

3421 Thorndyke Ave W

Seattle, Washington, 98199,

United States




Expert Collections containing Arzeda

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Arzeda is included in 3 Expert Collections, including Synthetic Biology.


Synthetic Biology

305 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.


Advanced Materials

1,326 items

Companies in the advanced materials space, including polymers, biomaterials, semiconductor materials, and more


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Arzeda Patents

Arzeda has filed 10 patents.

The 3 most popular patent topics include:

  • molecular biology
  • bioinformatics
  • biotechnology
patents chart

Application Date

Grant Date


Related Topics




Protein structure, Molecular biology, Bioinformatics, Transcription factors, Biotechnology


Application Date


Grant Date



Related Topics

Protein structure, Molecular biology, Bioinformatics, Transcription factors, Biotechnology



Latest Arzeda News

How Unilever uses AI to cut petrochemicals out of laundry soap

Nov 8, 2023

Source: Unilever Unilever is speeding development of petrochemical replacements for ingredients in its cleaning and laundry products with the help of artificial intelligence. It’s a strategy that will continue under new CEO Hein Shumacher, who has pointed to research and development in innovative disciplines — notably synthetic biology — as central to Unilever’s sustainability strategy. One example is Uniliever’s multiyear partnership with Arzeda , a Seattle-based company using physics-based computational protein design and machine learning to identify renewable and biodegradable proteins. Enzymes are responsible for chemical reactions. They’re also naturally derived, and Unilever sees them as one potential ingredient to help decarbonize products such as OMO, its largest detergent brand. "It is believed that only 5 percent of the enzymes that occur naturally have been identified and fully understood," said Neil Parry, head of biotech for Unilever, in July 2021 when the company’s Arzeda relationship was announced. "So when looking for new discoveries, it’s a bit like trying to find a needle in a haystack — then you need to tackle that one key find and optimize it to be as effective as possible in your application." So far, the two companies have identified enzymes that can eliminate stains while reducing the amount of energy and water used by cleaning products and potentially cutting the number of ingredients needed for certain products in half. They did this in just 18 months, five times faster than traditionally possible, Parry said this summer. "Not only can you optimize from the templates you have today, but you can create entirely novel models that you don’t have today," he said. This isn’t just about directing computers to solve a problem. Physicists, biologists and data analysts were all involved. As part of the process, Unilever’s design teams worked with Arzeda to create lists of requirements for its products, Parry said. The algorithms draw on past research to make suggestions, helping prioritize the most viable options. "It’s an amalgamation of the science, which is leading to a step change in how things are developed," he said. Arzeda, which raised a $33 million Series B round of venture funding in March 2022, doesn’t just help companies with discovery. It’s also a co-development partner. It has already worked with Unilever to design, engineer and test the enzymes in real-world testing quantities. The next step will be to scale production of the enzymes and help commercialize them. "We are getting better and better at the design with every undertaking," said Arzeda CEO Alexandre Zanghellini. The two companies declined to discuss their financial relationship or when the enzymes will actually show up in products, but Unilever is working against real deadlines. The company has committed to net-zero carbon emissions for its products "cradle to shelf" by 2039 and aims to make its product formulations biodegradable by 2030. "We’re not working on something that doesn’t have a tangible outcome," Parry said. [Want more great insight on technologies and trends accelerating the clean economy? Subscribe to our free Climate Tech Rundown newsletter. ] Show comments for this story. More on this topic

Arzeda Frequently Asked Questions (FAQ)

  • When was Arzeda founded?

    Arzeda was founded in 2007.

  • Where is Arzeda's headquarters?

    Arzeda's headquarters is located at 3421 Thorndyke Ave W, Seattle.

  • What is Arzeda's latest funding round?

    Arzeda's latest funding round is Series C.

  • How much did Arzeda raise?

    Arzeda raised a total of $70.62M.

  • Who are the investors of Arzeda?

    Investors of Arzeda include Bunge Ventures, Stage 1 Ventures, Bioeconomy Capital, Universal Materials Incubator, OS Fund and 11 more.

  • Who are Arzeda's competitors?

    Competitors of Arzeda include Cradle and 5 more.


Compare Arzeda to Competitors

EnginZyme Logo

EnginZyme is a cell-free synthetic biology company that develops a technology platform that combines enzymatic cascades with packed bed reactors. The company provides research and developmental services to companies in multiple industries, such as pharma, food, chemicals, and flavors and fragrances. It was founded in 2014 and is based in Solna, Sweden.

SciTech Development Logo
SciTech Development

SciTech Development is a clinical stage, biopharmaceutical company whose lead compound is an accelerated, short-development track, anti-cancer agent (nano-fenretinide or ST-001) delivered in an intravenous system initially for the management of an orphan T-cell lymphoma and then for a cadre of other tumor-types. The company was founded in 2001 and is based in Grosse Pointe, Michigan.

Insilico Medicine Logo
Insilico Medicine

Insilico Medicine operates as a clinical-stage biotechnology company operating in pharmaceutical research and development. It offers services that include novel target discovery, generation of molecular structures with desired properties, and clinical trial analysis, enabled by advanced machine learning techniques. Its services primarily cater to the healthcare industry, with a particular emphasis on the discovery and development of innovative drugs for a range of conditions including cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It was founded in 2014 and is based in New Territories, Hong Kong.

Aqemia Logo

Aqemia offers drug discovery software predicting the affinity between drug candidates and therapeutic targets responsible for diseases. It uses quantum and statistical mechanics algorithms fuelling a generative artificial intelligence (AI) to design drug candidates. The company was founded in 2019 and is based in Paris, France.

YDS Pharmatech

YDS Pharmatech is a company focused on drug discovery in the pharmaceutical industry. The company offers a platform for the design of new drug candidates, utilizing structure-based de novo drug design and evolutionary AI to accelerate the drug discovery process. YDS Pharmatech primarily serves the pharmaceutical industry. It was founded in 2020 and is based in Albany, New York.


Areta International was founded, with totally private financial support, by Dr. Maria Luisa Nolli in autumn 1999 as a spin-off of cell biology Laboratories of Lepetit Research Center, part of multinational companies, where she had a twenty years experience as scientist and team leader. nnThe company was born to cover the gap existing between the excellent basic research and the poor development of discoveries, with a view of helping customers to transform research projects in new potential biodrugs. nn nn


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.